Ashvattha’s new self-administered anti-VEGF therapy may address unmet needs for DME
Ashvattha Therapeutics’ D-4517.2 stands out among anti-VEGF treatments in that it can be self-administered using an autoinjector.
By
Cardiovascular
Latest in
Cardiovascular
Lilly announces results from SURPASS programme for T2D and obesity therapy Mounjaro
Further trials for pediatric and heart failure patients are currently ongoing.
By
NICE recommends Amarin’s icosapent ethyl to prevent cardiovascular events
With the latest development, the new treatment will benefit nearly 425,000 individuals.
BMS receives US FDA approval for Camzyos to treat cardiomyopathy
The approval is based on findings from Phase III EXPLORER-HCM clinical trial that enrolled 251 adults with obstructive HCM.
Kyttaro and Lilly sign licence agreement for monoclonal antibody programme
The antibodies showed potential for treating individuals who are at high-risk for atherosclerotic cardiovascular disease.
ACC 22: empagliflozin produces clinical benefits for patients with acute heart failure
The additional clinical benefits empagliflozin offers will strengthen its position in an increasingly competitive SGLT-2I class.
By
ACC 22: mavacamten improves health status in symptomatic hypertrophic cardiomyopathy
Mavacamten is a selective cardiac myosin inhibitor currently in pre-registration for hypertrophic cardiomyopathy (HCM) in the US.
By
EC approves Boehringer-Lilly’s Jardiance for chronic heart failure
The EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.